Navigation Links
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Date:5/8/2008

ARLINGTON HEIGHTS, Ill. Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume, according to a study in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). This new delivery technique, which has yet to be tested in humans, did not cause toxicity in the body of rats; however, administering the same anti-tumor agent intravenously in humans has previously been shown to cause liver damage.

This new technique may allow us to reprogram skin flaps, using gene therapy, to provide a blueprint for anti-tumor agents like Interleukin-12 to be produced in the tumor to kill cancer, while avoiding adverse side effects, said Geoffrey Gurtner, MD, ASPS Member and study senior author. In this study we took skin flaps in animal models and delivered IL-12 directly to the tumor area with tremendous success. Since skin flaps are used thousands of times each year in cancer patients, this may potentially open up an entirely new area in plastic surgery and bring the specialty, once again, to the center of medicine.

Gene therapy has been heralded as a new tool to restrain or prevent tumor growth and recurrence in humans, but its use has been limited because of serious side effects and the difficulty in concentrating anti-tumor agents at the site of the cancer.

In the study, skin flaps (a mass of healthy tissue) taken from rats were injected with the gene for IL-12 into the flaps blood supply. The flaps were then placed onto cancerous tumors on the rats.

The study found a 79 percent reduction in tumor volume for animals treated with IL-12 compared to control animals. The treatment allowed individual cells within the flap to become encoded with IL-12 and function as miniature factories producing the IL-12 protein at very high levels in the tumor site, according to the study.

Additionally, the serious side effects previously documented with systemic use of IL-12 were not found in the treated rats. The liver, lung and spleen remained normal throughout the study. The delivery technique through free flaps did not cause liver toxicity, whereas using IL-12 intravenously in humans has been shown to cause liver damage.

This could be a major advance for the delivery of a therapeutic agent to diseased parts of the body, said Dr. Gurtner. I can see this therapy being used for breast cancer, head and neck cancers, central nervous system malignancies, and somewhere down the line hemophilia, diabetes and infections.

The study authors concluded that as oncologic reconstructive surgery is a major component of plastic surgery, the delivery of a healing agent precisely to the region where cancer was and where local recurrences are most likely to occur, could add a new dimension to the reconstructive function of free flaps in oncologic and reconstructive plastic surgery.


'/>"/>

Contact: ASPS Media Relations
media@plasticsurgery.org
847-228-9900
American Society of Plastic Surgeons
Source:Eurekalert

Related medicine news :

1. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
2. KePROs Chief Medical Officer to Deliver Clinical Keynote Address
3. Doctors Discover Marker for Meconium Passage During Delivery
4. Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
5. Mothers with Breast Cancer Can Dine to Thrive with Gourmet Meal Delivery
6. Medco Joins Cincinnatis Cover the Uninsured Week Effort To Deliver Lower Cost Health Care
7. SpongeTech(R) Delivery Systems, Inc. Clarification of Yesterdays $7,500,000 Order of Uncle Normans(TM) Pet Sponge
8. LMS CALM(R) receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report
9. The Heritage Group Selects AccuNurse(R) to Improve Efficiency and Deliver Proactive Care
10. The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference
11. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: